ICE Bioscience Posters

Download

Antibody drug conjugates (ADCs) are a class of rapidly developing targeted biotherapeu- tic drugs, which consist of three elements: antibody, linker, and payload. ADCs combine the high specificity of antibodies with the potency of payloads, delivering the highly effi- cient small molecule within the target tumor cells.

As one of the new payload types, stimulator of interferon genes (STING) agonist can initi- ate the innate immune response, enhancing the attack on tumor cells. STING agonist ADCs, allowing tumor-localized activation of STING, may achieve greater anti-tumor ac- tivity and better tolerability.

By combining the STING binding assay, different THP-1 reporter assay, and cytokine re- lease detection, ICE Bioscience can support for STING agonist activities screening. West- ern blotting assay can be applied for demonstrating the molecular mechanisms of candi- dates. For specific screening and evaluation of HER2 STING agonist ADCs, cell binding assay, cell internalization assay, HER2 overexpression reporter assays, co-culture assays of tumor cell lines or STING knockout tumor cell lines with THP-1, hPBMC, as well as whole blood can be utilized at different project stages.